NHG's Catalyst AW: RWD & RWE for Evidence Generation in New Medicines

​RWD & RWE for Evidence Generation in New Medicines

​📅 Date: 22 April
📍 Location: NHG Stockholm Office
⏰ Time: 17:30–20:30

​Real-world data (RWD) and real-world evidence (RWE) are becoming increasingly important in shaping how new medicines are evaluated and introduced. By capturing insights from routine clinical practice, RWD and RWE help inform decision-making around drug utilization, safety, and effectiveness.

​The session will feature a keynote talk by Björn Wettermark, Professor of Pharmacoepidemiology at Uppsala University, followed by a moderated discussion and networking.

​In this keynote, Björn will share experiences from the Horizon MORE Europe project, exploring how RWD and RWE can support regulatory, health technology assessment (HTA), and clinical decisions in the context of new medicines.

​Agenda

• ​17:30 – Doors open

• ​18:00 – Welcome & introduction to NHG by Vesa Komssi, Executive Vice President at NHG, and Susanne Kihlblom, Senior Partner at NHG

• ​18:10 – Keynote: Björn Wettermark

• ​18:30 – Moderated discussion & audience Q&A

• ​18:50 – Mingle & networking with drinks and light bites

• ​20:30 – Bar closes

​About the Speaker

​Björn Wettermark, M.Sc.Pharm, PhD is Professor of Pharmacoepidemiology at Uppsala University and Visiting Professor at Vilnius University. His research focuses on drug utilization in health policy, including prescribing quality, international comparisons, sustainable prescribing, and evidence generation for new medicines.

​He has held several leadership roles within the Stockholm healthcare region and has contributed extensively to national and European initiatives. His experience includes serving as a scientific advisor to the Swedish Medical Products Agency and as Chair of the European Drug Utilization Research Group (EuroDURG).